Biotech & Pharmaceuticals

Celgene agrees to buy biotechnology company Juno Therapeutics for about $9 billion.

Sixty-four percent of patients achieved major depressive disorder remission using SAGE-217 in the 15th day of treatment, Sage says.

Inter partes review is at the center of a case before the Supreme Court, and the decision will have far-reaching effects.

The approvals “mark another significant milestone for our company,” Mylan CEO Heather Bresch says.

Arena Pharmaceuticals’ drug Ralienpag met its Phase 2 program goals.

Lilly says the FDA needed additional data to “characterize safety concerns across treatment arms.”

While the White House and Congress struggled to repeal Obamacare, investors did not shy away from health-care stocks in the first quarter.

United Therapeutics said it would be delaying the launch of an implantable pump until 2018.

The track record in drug development for Alzheimer’s disease has been terrible: a success rate of less than 1 percent.

Almost 200,000 people have fatally overdosed on opioids in the past 15 years, with more than 30,000 people dying in 2015 alone.

Traders are worried that Repatha isn’t effective enough to justify the drug’s hefty price tag of over $14,500 per year.

The drug, known as JCAR015, was being tested in adults with relapsed acute lymphoblastic leukemia, a rare and deadly blood cancer.

Express Scripts said despite the double-digit increase, costs for employers rose just 2.5 percent across all prescription drugs.

More than $125 million has been spent over an initiative to bar state agencies from paying more for drugs than the Veterans Affairs Department pays.